Profile data is unavailable for this security.
About the company
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
- Revenue in JPY (TTM)789.40bn
- Net income in JPY46.43bn
- Incorporated1941
- Employees13.51k
- LocationEisai Co LtdEisai Main Bldg., 4-6-10, KoishikawaBUNKYO-KU 112-8088JapanJPN
- Phone+81 338173700
- Fax+81 338113305
- Websitehttps://www.eisai.co.jp/
More ▼
Mergers & acquisitions
| Acquired company | 4523:TYO since announced | Transaction value |
|---|---|---|
| EcoNaviSta Inc | -3.17% | 108.23m |
Data delayed at least 15 minutes, as of Jul 03 2025 04:44 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tsumura & Co | 181.09bn | 32.43bn | 265.97bn | 4.27k | 8.11 | 0.8732 | 5.82 | 1.47 | 427.12 | 427.12 | 2,385.35 | 3,968.06 | 0.4058 | 0.72 | 2.73 | 42,390,680.00 | 7.74 | 5.53 | 9.75 | 6.85 | 50.02 | 49.39 | 19.06 | 14.50 | 2.62 | -- | 0.1766 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Hisamitsu Pharmaceutical Co Inc | 156.01bn | 21.76bn | 302.24bn | 2.80k | 13.61 | 1.06 | 10.55 | 1.94 | 295.53 | 295.53 | 2,116.23 | 3,794.07 | 0.4644 | 2.98 | 3.47 | 55,736,340.00 | 6.64 | 4.34 | 7.77 | 4.99 | 58.46 | 57.83 | 14.30 | 10.32 | 3.84 | -- | 0.0136 | 50.29 | 10.09 | 2.04 | 55.76 | 3.08 | 29.89 | 0.7127 |
| Sumitomo Pharma Co Ltd | 398.83bn | 23.63bn | 370.84bn | 3.83k | 15.67 | 2.18 | 7.54 | 0.9298 | 59.49 | 59.49 | 1,003.88 | 426.59 | 0.4834 | 1.46 | 5.96 | 104,079,300.00 | 2.86 | -5.49 | 5.29 | -8.49 | 61.53 | 67.88 | 5.93 | -13.24 | 0.6606 | 2.46 | 0.6496 | -- | 26.79 | -3.75 | 107.50 | -10.32 | -0.4856 | -- |
| Rohto Pharmaceutical Co Ltd | 308.63bn | 31.01bn | 483.46bn | 9.14k | 15.11 | 1.78 | 10.96 | 1.57 | 135.51 | 135.51 | 1,349.22 | 1,151.04 | 0.8037 | 2.47 | 4.46 | 33,751,640.00 | 8.06 | 8.59 | 10.78 | 11.70 | 56.68 | 57.78 | 10.03 | 10.57 | 1.65 | -- | 0.1924 | 21.12 | 13.95 | 10.38 | 0.2263 | 15.01 | 10.42 | 22.59 |
| Santen Pharmaceutical Co Ltd | 300.00bn | 36.25bn | 568.33bn | 3.85k | 16.04 | 1.98 | 10.56 | 1.89 | 103.60 | 103.60 | 858.37 | 838.52 | 0.7101 | 2.72 | 3.88 | 77,943,360.00 | 8.49 | 3.94 | 10.75 | 4.93 | 57.01 | 58.97 | 11.95 | 6.01 | 1.99 | -- | 0.1072 | 71.86 | -0.6494 | 4.43 | 36.09 | 8.94 | 3.61 | 5.92 |
| Ono Pharmaceutical Co Ltd | 486.87bn | 50.05bn | 767.74bn | 4.29k | 14.45 | 0.9243 | 9.96 | 1.58 | 106.52 | 106.52 | 1,036.36 | 1,665.60 | 0.4924 | 2.40 | 3.79 | 113,569,200.00 | 5.07 | 10.78 | 5.85 | 12.37 | 69.61 | 73.23 | 10.30 | 21.23 | 2.56 | 142.59 | 0.1569 | 36.33 | -3.14 | 10.73 | -60.89 | -3.47 | -18.66 | 12.20 |
| Eisai Co Ltd | 789.40bn | 46.43bn | 1.19tn | 13.51k | 24.86 | 1.37 | 13.50 | 1.50 | 163.81 | 163.81 | 2,784.17 | 2,982.52 | 0.5678 | 0.8644 | 4.47 | 58,448,100.00 | 3.46 | 3.81 | 4.68 | 5.14 | 78.62 | 77.46 | 6.09 | 6.44 | 1.37 | -- | 0.178 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Kyowa Kirin Co Ltd | 494.71bn | 51.40bn | 1.28tn | 5.67k | 25.04 | 1.53 | 16.70 | 2.59 | 97.34 | 97.34 | 939.97 | 1,588.59 | 0.4745 | 1.78 | 3.92 | 87,266,360.00 | 4.93 | 6.37 | 5.75 | 7.25 | 73.40 | 75.13 | 10.39 | 14.65 | 2.71 | 17.52 | 0.00 | 46.38 | 12.06 | 10.14 | -26.26 | 9.71 | 37.71 | 6.67 |
| Shionogi & Co Ltd | 438.27bn | 170.44bn | 2.27tn | 4.96k | 12.72 | 1.59 | 11.90 | 5.17 | 200.28 | 200.28 | 514.99 | 1,600.97 | 0.2969 | 0.979 | 3.61 | 88,449,650.00 | 11.49 | 12.17 | 12.69 | 13.74 | 85.44 | 84.91 | 38.68 | 38.30 | 6.13 | -- | 0.0158 | 27.87 | 0.7325 | 5.62 | 5.19 | 6.88 | 34.66 | 12.30 |
| Astellas Pharma Inc | 1.91tn | 50.75bn | 2.52tn | 13.64k | 50.48 | 1.65 | 10.07 | 1.32 | 27.56 | 27.56 | 1,062.16 | 845.25 | 0.5536 | 1.28 | 3.28 | 140,168,800.00 | 1.47 | 3.05 | 2.22 | 4.45 | 81.74 | 81.15 | 2.65 | 5.42 | 0.8516 | 4.00 | 0.3824 | 131.42 | 19.25 | 8.01 | 197.72 | -23.64 | -5.94 | 13.09 |
| Otsuka Holdings Co Ltd | 2.39tn | 350.74bn | 3.71tn | 35.34k | 10.50 | 1.37 | 8.00 | 1.55 | 650.78 | 650.78 | 4,433.96 | 5,000.59 | 0.6701 | 2.29 | 5.03 | 67,722,650.00 | 9.92 | 5.91 | 12.38 | 7.27 | 72.20 | 69.18 | 14.81 | 9.89 | 1.44 | -- | 0.0859 | 32.93 | 15.42 | 10.78 | 182.13 | 21.96 | 15.32 | 3.71 |
Data as of Jul 03 2025. Currency figures normalised to Eisai Co Ltd's reporting currency: Japanese Yen JPY
29.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 05 Jun 2025 | 18.37m | 6.30% |
| Wellington Management Co. LLPas of 30 May 2025 | 14.04m | 4.82% |
| The Vanguard Group, Inc.as of 04 Jun 2025 | 9.69m | 3.32% |
| Nikko Asset Management Co., Ltd.as of 29 Sep 2023 | 8.43m | 2.89% |
| Daiwa Asset Management Co. Ltd.as of 30 May 2025 | 8.29m | 2.84% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 29 Sep 2023 | 7.92m | 2.72% |
| BlackRock Japan Co. Ltd.as of 28 Feb 2025 | 6.02m | 2.06% |
| BlackRock Fund Advisorsas of 28 Feb 2025 | 5.40m | 1.85% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jun 2025 | 4.78m | 1.64% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 3.65m | 1.25% |
More ▼
Data from 31 Dec 2024 - 26 Jun 2025Source: FactSet Research Systems Inc.
